| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 호흡기
> 폐 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Over 100,000 | National | Regularly | 119011106646 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 신경근
> 근이영양증 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Regularly | 119021570524 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | 암
> 암: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 신장
> 신장 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | National | Regularly | 119051003447 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines. | 호흡기
> 천식 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Over 100,000 | National | Regularly | 119051065145 |
| PBAC [Pharmaceutical Benefits Advisory Committee] comments. | 스킨
> 아토피 피부염/습진 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Over 100,000 | National | Regularly | 119051082840 |
| HTA [Health Technology Assessment] — lived experience. | 호흡기
> 폐 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Over 100,000 | National | Regularly | 119051865995 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 희귀
> 희귀 질환: 유전성 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Sometimes | 119054286714 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 위장관
> IBD | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Over 100,000 | National | Regularly | 119058351283 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 심혈관
> 심혈관 및 심장 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | International | Regularly | 119061299937 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 정신 건강
> 정신 건강: 대부분의 상태 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Sometimes | 119074282308 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 호흡기
> 천식 | 규제 파트너십
> 마케팅 허가 제출에 기여 | Over 100,000 | National | Regularly | 119051065145 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 신경근
> 근이영양증 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | National | Regularly | 119021570524 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. | 정신 건강
> 정신 건강: 대부분의 상태 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 10,000 | National | Sometimes | 119074282308 |
| Regular advocacy and lobbying to all levels of government on new and current diabetes medications and technology. | 내분비
> 당뇨병(1형 및 2형 모두) | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | Over 100,000 | National | Regularly | 119023443093 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 호흡기
> 천식 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | Over 100,000 | National | Regularly | 119051065145 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 위장관
> IBD | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | Over 100,000 | National | Regularly | 119058351283 |
| Where possible, we add our advocacy voice to decision-makers. | 신경근
> 근이영양증 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 1,000 | National | Rarely | 119070072574 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 신장
> 신장 질환 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | Do not know | National | Regularly | 119051003447 |
| Public submissions. | 의학 연구
> 의학 연구 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 100 | National | Sometimes | 119075599019 |
| Pre-Budget Submissions, Advocacy activities, Meetings. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | Over 100,000 | National | Regularly | 119017682842 |
| Weight loss drugs, general medicine costs. | 환자 권익 옹호
> 환자 권리 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 100,000 | National | Sometimes | 119055318270 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 위장관
> IBD | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | Over 100,000 | National | Regularly | 119058351283 |
| Pricing. | 류마티스성
> 루푸스 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | International | Regularly | 119058972997 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 신경학적
> 신경학적: 기타 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 전염성
> 예방접종 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | 뼈
> 진행성 골화성 섬유이형성증(FOP) | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100 | National | Rarely | 119044789085 |
| Australia's PBS [Pharmaceutical Benefits Scheme] listings as an example. | 신장
> 신장 질환 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 5,000 | National | Regularly | 119050789619 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 희귀
> 희귀 질환: 유전성 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | National | Sometimes | 119054286714 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 정신 건강
> 정신 건강: 대부분의 상태 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 10,000 | National | Sometimes | 119074282308 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 신경근
> 근이영양증 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Regularly | 119021570524 |
| Weight loss drugs, general medicine costs. | 환자 권익 옹호
> 환자 권리 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100,000 | National | Sometimes | 119055318270 |
| Regulations and restrictions regarding prescribing of antivirals for COVID to our patient cohort [neurological conditions]. | 신경학적
> 신경학적: 기타 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 5,000 | National | Rarely | 119056702514 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 심혈관
> 심혈관 및 심장 질환 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | Do not know | International | Regularly | 119061299937 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 신경학적
> 신경학적: 기타 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| Through an HTA [Health Technology Assessment] implementation review. | 신경학적
> 신경학적: 기타 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 전염성
> 예방접종 | 접근 경로 개선
> 더 넓은 백신 접근성을 위해 옹호하기 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | 뼈
> 진행성 골화성 섬유이형성증(FOP) | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | National | Rarely | 119044789085 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 신장
> 신장 질환 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | Do not know | National | Regularly | 119051003447 |
| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 호흡기
> 폐 질환 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | Over 100,000 | National | Regularly | 119011106646 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | 암
> 암: 대부분의 유형 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| HTA [Health Technology Assessment] — lived experience. | 호흡기
> 폐 질환 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | Over 100,000 | National | Regularly | 119051865995 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 정신 건강
> 정신 건강: 대부분의 상태 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | 10,000 | National | Sometimes | 119074282308 |
| Pricing, clinical trials. | 류마티스성
> 루푸스 | 진단 및 의약품 배달
> 임상 시험 설계에 대해 협력하기 | 5,000 | International | Regularly | 119058972997 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 희귀
> 희귀 질환: 유전성 | 진단 및 의약품 배달
> 검진 및 조기 발견 지원 | 1,000 | National | Sometimes | 119054286714 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 희귀
> 희귀 질환: 유전성 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 1,000 | National | Sometimes | 119054286714 |
| Preterm Infants Parents Association [PIPA] has representatives on numerous hospital and Queensland Health Department committees. | 어린이 건강
> 신생아 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 5,000 | Regional | Regularly | 119074312093 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 신경학적
> 신경학적: 기타 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | We do not communicate with patients directly | National | Regularly | 119069368666 |
상호작용
활동 및 옹호
14 멘션
